How much funding has BioRegenx raised?

BioRegenx has disclosed $798.5K raised across 2 rounds.

Where is BioRegenx headquartered?

BioRegenx is headquartered in Chattanooga, US.

BioRegenx

OTC: BRGX

Chattanooga, US · Founded 2021 · Nevada corporation

BioRegenx develops hardware and software for microscopy imaging of the endothelial glycocalyx, along with microvascular regenerative products, serving doctors, research scientists, and wellness consumers. The company combines diagnostic imaging technology with regenerative therapeutics in the medical device and wellness sector.

AI & Machine Learning Biotech Healthtech Longevity Medical Devices

Founders & leadership

Hans VinkExecutive

William ResidesExecutive

Robert LongExecutive

Gary HennerbergExecutive

Hitesh JunejaExecutive

Board

Sherri AdamsBoard director

Suzanne BirdBoard director

Jody WalkerBoard director

Reported raises · per SEC filings

Form D private placements

$798.5K disclosed across 2 rounds · 2021–2023

▶$183KraisedApr 2023 · 5 investors · Biotechnology

Rule 506(c)

Officers, directors & promoters on the filing

Joseph S BirdPromoter
Robert DoranPromoter
Sherri AdamsDirector
Suzanne BirdDirector
Hans VinkExecutive Officer, Director, Promoter
William ResidesExecutive Officer, Director, Promoter
Robert LongExecutive Officer, Director, Promoter
Jody WalkerDirector
Gary HennerbergExecutive Officer, Director
Hitesh JunejaExecutive Officer

Offering amount: $3.6M
Amount sold: $183K
Proceeds to insiders: $150K
First sale: Jan 2023
Incorporated: Corporation, Nevada, 2021
Federal exemptions: 06c

Full filing on SEC EDGAR ↗

▶$615.5KraisedAug 2021 · 23 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

William ResidesExecutive Officer, Director, Promoter
Robert LongExecutive Officer, Director, Promoter
Gary Dale HennerbergExecutive Officer, Director, Promoter
Hans VinkExecutive Officer, Director, Promoter
Robert DoranExecutive Officer, Director, Promoter
Joseph Simmons Bird, Jr.Executive Officer, Director, Promoter

Offering amount: $3M
Amount sold: $615.5K
Proceeds to insiders: $945.9K
First sale: Jul 2021
Incorporated: Corporation, Nevada, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Regenx Biosciences12 shared keywordsREGENXBIO is a gene therapy company developing treatments for rare and retinal diseases using its NAV Technology Platform of viral vectors, which it also licenses to other pharmaceutical and biotech companies. It operates a late-stage clinical pipeline and manufactures its investigational gene therapies at its facility in Rockville, MD.

Companies competing with BioRegenx for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

BioRegenx, Inc. (OTC: BRGX) Announces Major Corporate Progress, Auditor Transition, Technology Integration, and AI-Driven Strategic Vision - BioSpacebiospace.com · Dec 2025

BioRegenx Announces Investor Update - Bioregenxbioregenx.com · Jul 2022

Frequently asked questions

What does BioRegenx do?: BioRegenx develops hardware and software for microscopy imaging of the endothelial glycocalyx, along with microvascular regenerative products, serving doctors, research scientists, and wellness consumers. The company combines diagnostic imaging technology with regenerative therapeutics in the medical device and wellness sector.
How much funding has BioRegenx raised?: BioRegenx has disclosed $798.5K raised across 2 rounds.
Where is BioRegenx headquartered?: BioRegenx is headquartered in Chattanooga, US.